PIPELINE
SCROLL
GAlA Platform
RN0361
Hypertriglyceridemia ApoC3
Preclinical
IND-Enabling
Ph1
Ph2
Ph3
RN0191
Hypercholesterolemia PCSK9
Preclinical
IND-Enabling
Ph1
Ph2
Ph3
RN3161
Obesity INHBE
Preclinical
IND-Enabling
Ph1
Ph2
Ph3
RN1871
Hypertension AGT
Preclinical
IND-Enabling
Ph1
Ph2
Ph3
RN5681
ASCVD Lp(a)-PCSK9
Preclinical
IND-Enabling
Ph1
Ph2
Ph3
RN3271
Cardiomyopathy TTR
Preclinical
IND-Enabling
Ph1
Ph2
Ph3
RNK288
IgAN Undisclosed
Preclinical
IND-Enabling
Ph1
Ph2
Ph3
RNN798
MASH, Hyperlipidemia CIDEB
Preclinical
IND-Enabling
Ph1
Ph2
Ph3
RN679
Metabolic Syndrome Undisclosed
Preclinical
IND-Enabling
Ph1
Ph2
Ph3
RN609
Metabolic Syndrome Undisclosed
Preclinical
IND-Enabling
Ph1
Ph2
Ph3
APOLLO Platform
RN596
Obesity Undisclosed
Preclinical
IND-Enabling
Ph1
Ph2
Ph3
RN508
Obesity Undisclosed
Preclinical
IND-Enabling
Ph1
Ph2
Ph3
RN517
Metabolic Diseases Undisclosed
Preclinical
IND-Enabling
Ph1
Ph2
Ph3
RN201
Epilepsy Undisclosed
Preclinical
IND-Enabling
Ph1
Ph2
Ph3
RN276
AD Tau(Cross BBB)
Preclinical
IND-Enabling
Ph1
Ph2
Ph3
Jinyu Huang, Ph.D.
Chief Executive Officer, Founder
Stella Shi is founder, Chief Executive Officer and chairs the board of Rona Therapeutics since company inception in 2021 bringing ~15 years of biopharmaceutical industry and venture capital experience. Prior to founding Rona Therapeutics, Stella was managing director in Lilly Asia Ventures (LAV) from 2015 with proven track records with various venture creation ...